In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Modified form Tesamorelin | Synthetic fragment Sermorelin | |
|---|---|---|---|
| Identity | |||
| Kind | Modified form | Synthetic fragment | |
| Area | Growth hormone axis | Growth hormone axis | |
| Evidence | |||
| Amount of evidence | 288 | 304 (plus 5 on natural levels, listed separately) | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 43 (34 in people) | 30 (30 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 23 · 3 active1 more mentions it but does not test it | None registered2 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
The FDA label for Egrifta says: “Reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy” No central EU authorisation (EMA).
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Tesamorelin | Sermorelin |
|---|---|---|
| Growth hormone and IGF-1Endocrine and hormones | 22193 | 16113128 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The maker told the FDA it stopped selling the product. The FDA later found that the products were not withdrawn from sale for reasons of safety or effectiveness.
| Adverse eventsWhole body | 29236 | 1717 |
|---|
| Body weightMetabolic and weight | 39354 | 312 |
|---|
| Glycemic controlMetabolic and weight | 28253 | 77 |
|---|
| Immune responseImmune and inflammation | 55 | 31247 |
|---|
| Body compositionMusculoskeletal | 2727 | 33 |
|---|
| PharmacokineticsPharmacology | 18792 | 271665 |
|---|
| LipidsMetabolic and weight | 22211 | 11 |
|---|
| SleepSleep | 11 | 11 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Tesamorelin is the same as Somatorelin, human GHRH(1-44) residues 1 to 44, with 2 added groups.
What is different
Sermorelin is the same as Somatorelin, human GHRH(1-44) residues 1 to 29, with 1 added group.
What is different
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Tesamorelin | Sermorelin |
|---|---|---|
| Body compositionMetabolic and weightCompared as: difference from placebo, in % | −15.4% Treatment effect on VAT Dose studied: 2 mg26 weeksn = 8062010 | No comparable result 3 randomized-trial results measure it in another way or another unit. |
| LipidsMetabolic and weightCompared as: difference from placebo, in % | −12.3% Treatment effect on triglycerides Dose studied: 2 mg26 weeksn = 8062010 | No comparable result 1 randomized-trial result measure it in another way or another unit. |
| Growth hormone and IGF-1Endocrine and hormonesCompared as: difference from placebo, in μg/liter | 92 μg/liter Treatment effect on IGF-I Dose studied: 2 mg12 monthsn = 602012 | No comparable result 39 randomized-trial results measure it in another way or another unit. |
| Body weightMetabolic and weightCompared as: difference from placebo, in cm2 | −42 cm2 Treatment effect Dose studied: 2 mg6 monthsn = 482014 | No comparable result |
| Glycemic controlMetabolic and weightCompared as: difference from placebo, in mg/dl | 7 mg/dL Treatment effect Dose studied: 2 mg6 monthsn = 482014 | No comparable result |
−15.4%
Treatment effect on VAT
Dose studied: 2 mg26 weeksn = 8062010
No comparable result
3 randomized-trial results measure it in another way or another unit.
1 randomized-trial result measure it in another way or another unit.
4 randomized-trial results measure it in another way or another unit.
−12.3%
Treatment effect on triglycerides
Dose studied: 2 mg26 weeksn = 8062010
No comparable result
1 randomized-trial result measure it in another way or another unit.
92 μg/liter
Treatment effect on IGF-I
Dose studied: 2 mg12 monthsn = 602012
No comparable result
39 randomized-trial results measure it in another way or another unit.
−42 cm2
Treatment effect
Dose studied: 2 mg6 monthsn = 482014
No comparable result
1 randomized-trial result measure it in another way or another unit.
7 mg/dL
Treatment effect
Dose studied: 2 mg6 monthsn = 482014
No comparable result
4 randomized-trial results measure it in another way or another unit.
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 23 trials, ranked by phase, then posted results and enrollment: 2 completed · 1 stopped early · 2 with posted results · source ClinicalTrials.gov (opens in a new tab)
Theratechnologies263 participantsAug 2007 to Oct 2008
Lipodystrophy · HIV Infections
Columbia University6 participants7 Feb 2018 to 30 Apr 2025
HIV Lipodystrophy Syndrome · Growth Hormone Deficiency · Body Composition
Theratechnologies412 participantsJun 2005 to Apr 2007
HIV Infections · Lipodystrophy
1 more mentions it but does not test it. They only measure it or name it in their text.
No registered trial that tests Sermorelin found in ClinicalTrials.gov.
2 more mention it but do not test it. They only measure it or name it in their text.